Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis
- PMID: 40108967
- PMCID: PMC11923506
- DOI: 10.1002/jmv.70314
Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis
Abstract
Human coronavirus OC43 (HCoV-OC43) is predominantly associated with mild respiratory infections. HCoV-OC43 also has neuroinvasive properties, and severe encephalitis has been described in immunocompromised patients, with fatal outcomes due to the lack of specific antiviral treatment. We report a case of severe febrile encephalitis attributed to HCoV-OC43 that progressively worsened over 3 months in a 65-year-old immunocompromised man. Clinical symptoms improved remarkably after treatment with remdesivir, with an increase of the Glasgow Coma Score from 8 to 14 within 7 days.
Keywords: encephalitis; human coronavirus OC43; immunodeficiency; remdesivir.
© 2025 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
 
              
              
              
              
                
                
                 
              
              
              
              
                
                
                References
- 
    - Morfopoulou S., Brown J. R., Davies E. G., et al., “Human Coronavirus OC43 Associated With Fatal Encephalitis,” New England Journal of Medicine 375 (2016): 497–498. - PubMed
 
- 
    - Nilsson A., Edner N., Albert J., and Ternhag A., “Fatal Encephalitis Associated With Coronavirus OC43 in an Immunocompromised Child,” Infectious Diseases 52 (2020): 419–422. - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
 
        